Dr. Shiow-Lin Pan is a current Professor of Graduate Institute of Cancer Molecular Biology and Drug Discovery and the Director of Ph.D. Program in Biotechnology Research and Development of Taipei Medical University, Taipei, Taiwan. Dr. Pan’s work has centered around drug discovery and development for over 25 years. She led teams of professional scientists ranging from computational modeling, target identification, in vitro and in vivo efficacy validation, and toxicology. She also led multiple drug discovery projects for small molecules and antibody drugs. She has three IND submission experiences in the oncology field of drug discovery. She also led the phase 1 clinical study and finished the trial in 2019 Q4 for a novel HDAC inhibitor, MPT0E028, which is the first initiated drug development by a university in Taiwan. This work has been honored with the 16th National Innovation Award in Taiwan for academic research institute developing novel therapeutics. Dr. Pan current focus is leading a selective epigenetic inhibitor project for multiple myeloma and Alzheimer’s disease treatment. She has substantial experience in the disease animal models in oncology, neurodegeneration, inflammation, and cardiovascular fields. As a leader of an extensive research group, Dr. Pan also has substantial experience in mentoring research staff, graduate and undergraduate students at university. However, she has a unique background for bridging academic research and industrial drug development. Besides, Dr. Pan currently created a start-up company, ATP BioPharm, from TMU, and joined partnering events pitching developmental projects to pharmaceutical companies and potential investors to commercialize research work.

Dr. Pan Lab focused on drug discovery, primarily in anti-cancer and anti-neurodegenerative diseases. She leads a team of drug discovery researchers in professional fields, including machine learning, AI-based analysis, pharmacology, and disease animal models. Her primary focus is on pharmacology and toxicology studies. As a Principal Investigator of MOST Academia-Industry Research Project and MOST Grant for Applied Research Incubation Project in drug discovery. She also served as Co-PI for Taiwan Reputed University Startups to Taiwan Unicorns in developing E3 ligase inhibitors for anti-cancer activity. However, Dr. Pan has discovered and developed four drug candidates, including one candidate MPT0E028 in the Phase I/II trial, two candidates MPT0B640 and MPT0L056 in the Phase I trial, and one candidate MPT0G211 at the pre-IND enabling stage. MPT0E028, a pan-HDAC inhibitor for anti-cancer drug, has completed Phase I clinical trials in 2019. MPT0B640 and MPT0L056 were licensed to a Biotech company. MPT0G211, a selective HDAC6 inhibitor, will finish IND-enabling studies in Q3 2024 and be licensed to startup company ATP BioPharm.